JonesTrading Initiates Coverage of Prime Medicine (PRME) with Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, JonesTrading initiated coverage of Prime Medicine (NYSE:PRME) with a Buy recommendation.
Analyst Price Forecast Suggests 89.83% Upside
As of August 31, 2023, the average one-year price target for Prime Medicine is 22.78. The forecasts range from a low of 18.18 to a high of $28.35. The average price target represents an increase of 89.83% from its latest reported closing price of 12.00.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Prime Medicine is 2MM, an increase of %. The projected annual non-GAAP EPS is -2.02.
What is the Fund Sentiment?
There are 102 funds or institutions reporting positions in Prime Medicine. This is an increase of 3 owner(s) or 3.03% in the last quarter. Average portfolio weight of all funds dedicated to PRME is 0.15%, an increase of 11.91%. Total shares owned by institutions increased in the last three months by 106.43% to 9,241K shares. The put/call ratio of PRME is 0.37, indicating a bullish outlook.
